When did Lamictal (lamotrigine) get its EU patent protection end?
The exact date depends on which specific patent family and country-specific “last relevant expiry” the question refers to (for example, whether you mean the original active-ingredient patent, a formulation/process patent, or an SPC-based extension).
From the information provided, there’s not enough detail to determine Lamictal’s exact EU patent expiry date.
Which EU expiry matters for “Lamictal” in practice?
For EU-based drug launches and generic entry, people usually mean the end of the rights that block other companies from making/marketing a competing product. That can be driven by:
- the underlying active-substance patent expiry, or
- an SPC (supplementary protection certificate) and its end date (if one was granted), or
- additional related patents (formulation, polymorph, dosing regimen, manufacturing), each with their own expiry windows.
Without the specific patent number/family or the member state/SPC reference, a single “EU patent expiry date” can’t be stated accurately.
What you can do to get the exact expiry date
If you share one of the following, I can tell you the most likely EU expiry date for the relevant protection:
- the patent number or the INN (“lamotrigine”) patent family you mean, or
- the country within the EU (e.g., UK vs EU member state matters), or
- the marketing authorization holder and/or SPC reference, if you have it.
Quick clarification questions
1) Do you mean expiry of the original active-ingredient patent, or the SPC-extended expiry?
2) Which EU country are you looking at (or do you mean Europe-wide “last expiry”)?
Sources: None provided.